Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications.

被引：0

作者：

Perets, Ruth

Sharma, Manish

Strickler, John H.

Golan, Talia

Hollebecque, Antoine

Henner, William

Vasilopoulos, Athanasios

Thiele, Gladys Morrison

Burns, Michael Charles

Harding, James J.

机构：

[1] Technion Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel

[2] START Midwest, Grand Rapids, MI USA

[3] Duke Univ, Sch Med, Durham, NC USA

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Inst Gustave Roussy, Villejuif, France

[7] AbbVie Inc, N Chicago, IL USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3162

引用

页数：1